Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Wall Street's major averages took home gains on Friday, with the S&P 500 reclaiming the 6,000 level for the first time since late February, as sentiment was boosted by a strong May jobs report.

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.

Credit: K KStock/Adobe Stock Evernorth is heating up the anti-obesity drug price wars. Evernorth — the Cigna division that ... and help them lose weight. Novo Nordisk's Wegovy contains ...

The Cigna Group (NYSE ... in advance of the Inflation Reduction Act’s 2027 Medicare drug pricing reductions, which will benefit Novo’s products. Eli Lilly states that it remains committed ...

Until now, they benefited from FDA-permitted compounded versions of these drugs, often sold at lower prices due to the originals ... faster than a drive-thru at midnight. Cigna’s deal directly with ...

Cigna’s (NYSE:CI ... out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo Nordisk (NVO) and Eli Lilly’s (NYSE:LLY) Zepbound.